The U.S. Food and Drug Administration (FDA) has begun reviewing R.J. Reynolds Vapor Co.’s Vuse e-cigarette to determine whether or not the company can use a modified risk claim on its products.
Reynolds submitted Vuse for FDA review on Oct. 11, 2019 with the hopes of gaining premarket approval for several Vuse e-cigarette products. As part of the review process, the FDA will consider the product’s existing risks and benefits to the general population, including non-users, as it compares to traditional cigarettes. If deemed to present fewer risks than the traditional cigarette, the company will be able to market Vuse with modified risk claims. Vuse is the second best-selling e-cigarette in the U.S., marketed to adult consumers.
Continue Reading On: TobaccoBusiness.com